4
Changes in Ownership
Aclaris Therapeutics, Inc. Filed Acc 0001415889-25-002938
Chief Business Officer gave up 15,447 shares (to pay taxes)
- Chief Business Officer acquired 33,500 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Loerop James Chief Business Officer | 2025-02-01 | Option exercise | +11,250 | 96,503 | D | ||
| Loerop James Chief Business Officer | 2025-02-01 | Option exercise | +7,500 | 104,003 | D | ||
| Loerop James Chief Business Officer | 2025-02-01 | Option exercise | +14,750 | 118,753 | D | ||
| Loerop James Chief Business Officer | 2025-02-01 | Shares withheld for taxes | −15,447 | $2.48 | $38,309 | 103,306 | D |
| Derivatives | |||||||
| Loerop James Chief Business Officer | 2025-02-01 | Option exercise · Restricted Stock Units | −11,250 | 11,250 | D | ||
| Loerop James Chief Business Officer | 2025-02-01 | Option exercise · Resticted Stock Units | −7,500 | 15,000 | D | ||
| Loerop James Chief Business Officer | 2025-02-01 | Option exercise · Restricted Stock Units | −14,750 | 44,250 | D | ||
| Loerop James Chief Business Officer | 2025-02-03 | Grant or award · Restricted Stock Units | +83,500 | 83,500 | D | ||
| Loerop James Chief Business Officer | 2025-02-03 | Grant or award · Employee Stock Option (Right to Buy) | +292,300 | 292,300 | D | ||
Loading xslF345X05/form4-02042025_040201.xml…